Zimbuck – Your Market. Your Community.
BREAKING: Vir Biotechnology's hepatitis combo hits its Phase 3 goal.

Vir Biotechnology (Nasdaq: VIR) on Sunday announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial of monthly elebsiran plus tobevibart in adults with chronic hepatitis delta (company announcement).

The trial enrolled 124 patients and met its primary endpoint: 44% achieved undetectable virus plus ALT normalization at Week 48, versus 0% in the delayed-treatment group (p<0.0001). The key secondary endpoint was also met, with 79% reaching undetectable virus at Week 48, and 100% achieving virologic response at Week 24. The regimen was well tolerated, with no treatment interruptions or discontinuations.

Vir plans a U.S. FDA filing in mid-2027, with ECLIPSE 2 and ECLIPSE 3 data expected in Q1 2027. The company discusses the results on a call Monday, Nov 9 at 8:30 a.m. ET.

#VirBiotechnology #Biotech #Stocks #Nasdaq #Healthcare #ClinicalTrial #Markets
Like
Love
9
229 Views